Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.47 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.47 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.47 |
| ▸ | TYK2 known ✓ | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.47 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 14/20 | 0.68 |
| ▸ | CDK1 | P06493 | 13/20 | 0.68 |
| ▸ | CCND1 | P24385 | 12/20 | 0.68 |
| ▸ | CDK9 | P50750 | 11/20 | 0.68 |
| ▸ | CDK2 | P24941 | 11/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 10/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.68 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.68 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.68 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.68 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.68 |
| ▸ | CCND3 | P30281 | 4/20 | 0.68 |
| ▸ | GSK3A | P49840 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL3106724 | 1.00 | CDK4 (0.68) | CDK4CDK1CCND1CDK9CDK2 | |
| Fumaric Acid SCHEMBL3106742 | 1.00 | CDK4 (0.68) | CDK4CDK1CCND1CDK9CDK2 | |
| Fumaric Acid SCHEMBL3106735 | 1.00 | CDK4 (0.68) | CDK4CDK1CCND1CDK9CDK2 | |
| Acetic Acid SCHEMBL3105601 | 0.94 | CDK4 (0.71) | CDK4CDK1CCND1CDK9CDK2 | |
| Acetic Acid SCHEMBL3105617 | 0.94 | CDK4 (0.71) | CDK4CDK1CCND1CDK9CDK2 | |
| SCHEMBL291053 | 0.94 | CDK4 (0.75) | CDK4CDK1CCND1CDK9CDK2 | |
| SCHEMBL291052 | 0.94 | CDK4 (0.75) | CDK4CDK1CCND1CDK9CDK2 | |
| SCHEMBL291051 | 0.94 | CDK4 (0.75) | CDK4CDK1CCND1CDK9CDK2 | |
| SCHEMBL6524830 | 0.94 | CDK4 (0.75) | CDK4CDK1CCND1CDK9CDK2 | |
| Hydrochloric Acid SCHEMBL3108722 | 0.94 | CDK4 (0.75) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | claimed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | claimed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| EP-2046738-B1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL ENTPR LTD (IN) | 2014-06-11 | — | — | EP | disclosed |
| US-8563596-B2 | Enantiomerically pure compounds for the treatment of proliferative disorders | Piramal Enterprises Limited (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | EGFR 311/4885JAK2 495/4885ERBB2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.